Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 3/20 | 0.45 |
| ▸ | MVD | P53602 | 1/20 | 0.31 |
| ▸ | FNTA | P49354 | 4/20 | 0.31 |
| ▸ | FNTB | P49356 | 2/20 | 0.31 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2995247 | 0.91 | BTN3A1 (0.54) | BTN3A1MVDFNTAFNTBPGGT1B | |
| SCHEMBL2999012 | 0.87 | BTN3A1 (0.44) | BTN3A1 | |
| SCHEMBL3000757 | 0.85 | BTN3A1 (0.43) | BTN3A1 | |
| SCHEMBL6462210 | 0.79 | BTN3A1 (0.35) | BTN3A1 | |
| SCHEMBL8757061 | 0.78 | TSHR (0.35) | BTN3A1 | |
| SCHEMBL28251049 | 0.73 | BTN3A1 (0.50) | BTN3A1MVDFNTAFNTBPGGT1B | |
| SCHEMBL22235266 | 0.73 | BTN3A1 (0.66) | BTN3A1MVDFNTAFNTBPGGT1B | |
| SCHEMBL19472455 | 0.71 | BTN3A1 (0.36) | BTN3A1 | |
| SCHEMBL2455670 | 0.68 | BTN3A1 (0.32) | BTN3A1 | |
| SCHEMBL7260763 | 0.67 | HSD17B10 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100254940-A1 | Compositions and Methods for Regulating an Immune Response in a Subject | INNATE PHARMA, S.A. (FR) | 2010-10-07 | — | — | US | disclosed |
| US-20100189681-A1 | Methods of Using Phosphoantigens Together with Interleukin-2 for the Treatment of Cancer | INNATE PHARMA S.A. (FR) | 2010-07-29 | — | — | US | disclosed |
| US-20100029674-A1 | Methods of Using Phosphoantigen for the Treatment of Cancer | INNATE PHARMA, S.A. (FR) | 2010-02-04 | — | — | US | disclosed |
| US-20090304688-A1 | Methods and Compositions for Increasing the Efficiency of Therapeutic Antibodies Using Gamma Delta T Cell Activators | INNATE PHARMA S.A. (FR) | 2009-12-10 | — | — | US | disclosed |
| EP-2083830-A1 | IMPROVED METHODS OF USING PHOSPHOANTIGEN FOR THE TREATMENT OF CANCER | Innate Pharma (FR) | 2009-08-05 | — | — | EP | disclosed |
| EP-2040750-A2 | METHODS AND COMPOSITIONS FOR INCREASING THE EFFICIENCY OF THERAPEUTIC ANTIBODIES USING GAMMA DELTA T CELL ACTIVATORS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008059052-A9 | IMPROVED METHODS OF USING PHOSPHOANTIGEN FOR THE TREATMENT OF CANCER | INNATE PHARMA (FR) | 2009-03-12 | — | — | WO | disclosed |
| US-20080300222-A1 | Phosphoantigen Salts Of Organic Bases And Methods For Their Crystallization | INNATE PHARMA (FR) | 2008-12-04 | — | — | US | disclosed |
| EP-1948195-A2 | IMPROVED METHODS OF USING PHOSPHOANTIGEN FOR THE TREATMENT OF CANCER | Innate Pharma (FR) | 2008-07-30 | — | — | EP | disclosed |
| EP-1933848-A2 | PHOSPHOANTIGEN SALTS OF ORGANIC BASES AND METHODS FOR THEIR CRYSTALLIZATION | Innate Pharma (FR) | 2008-06-25 | — | — | EP | disclosed |
| WO-2008059052-A1 | IMPROVED METHODS OF USING PHOSPHOANTIGEN FOR THE TREATMENT OF CANCER | INNATE PHARMA (FR) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008006895-A2 | METHODS AND COMPOSITIONS FOR INCREASING THE EFFICIENCY OF THERAPEUTIC ANTIBODIES USING GAMMA DELTA T CELL ACTIVATORS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2008-01-17 | — | — | WO | disclosed |
| US-20070134273-A1 | Composition and method for the treatment of carcinoma | ROMAGNE FRANCOIS | 2007-06-14 | — | — | US | disclosed |
| WO-2007057440-A2 | IMPROVED METHODS OF USING PHOSPHOANTIGEN FOR THE TREATMENT OF CANCER | INNATE PHARMA (FR) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007039635-A2 | PHOSPHOANTIGEN SALTS OF ORGANIC BASES AND METHODS FOR THEIR CRYSTALLIZATION | INNATE PHARMA (FR) | 2007-04-12 | — | — | WO | disclosed |
| EP-1720567-A2 | COMPOSITION AND METHOD FOR THE TREATMENT OF CARCINOMA | Innate Pharma (FR) | 2006-11-15 | — | — | EP | disclosed |
| US-20060194755-A1 | Compositions and methods for regulating an immune response in a subject | INNATE PHARMA, S.A.S. (FR) | 2006-08-31 | — | — | US | disclosed |
| WO-2006067635-A2 | USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT | INNATE PHARMA S.A. (FR) | 2006-06-29 | — | — | WO | disclosed |
| WO-2005077411-A2 | COMPOSITION AND METHOD FOR THE TREATMENT OF CARCINOMA | INNATE PHARMA (FR) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100254940-A1 | Compositions and Methods for Regulating an Immune Response in a Subject | IFNG, IL2, ICOS | BTN3A1 288/4885MVD 4043/4885FNTA 1683/4885 |
| US-20100029674-A1 | Methods of Using Phosphoantigen for the Treatment of Cancer | CD4, CD74, TP53 | BTN3A1 536/4885MVD 909/4885FNTA 3378/4885 |
| US-20080300222-A1 | Phosphoantigen Salts Of Organic Bases And Methods For Their Crystallization | HLA-B, LCK, HLA-A | BTN3A1 875/4885MVD 2854/4885FNTA 2489/4885 |
| US-20100189681-A1 | Methods of Using Phosphoantigens Together with Interleukin-2 for the Treatment of Cancer | IL2, IL2RA, CD4 | BTN3A1 539/4885MVD 2950/4885FNTA 1180/4885 |
| US-20070134273-A1 | Composition and method for the treatment of carcinoma | IFNG, IL2, PBK | BTN3A1 155/4885MVD 2883/4885FNTA 219/4885 |
| US-20060194755-A1 | Compositions and methods for regulating an immune response in a subject | IFNG, IL2, ICOS | BTN3A1 279/4885MVD 4114/4885FNTA 1767/4885 |
| US-20090304688-A1 | Methods and Compositions for Increasing the Efficiency of Therapeutic Antibodies Using Gamma Delta T Cell Activators | CD4, FCGR3B, IFNG | BTN3A1 135/4885MVD 3676/4885FNTA 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.